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Abstract Androgen receptors are expressed at a low level 
in the cell line PC-3, which does not respond to either 
androgens or antiandrogens. If  these cells are exposed to 
natural beta-interferon (13-IFN) a reduction in cell growth 
and an increase in androgen receptors, evaluated by both 
biochemical and immunocytochemical techniques, occur. 
This increase seems not to be related to a selective block of 
PC-3 in any phase of the cell cycle. Pretreatment with 13- 
IFN determines in PC-3 cells a partial responsiveness to 
the androgen dihydrotestosterone as reflected by the 
increase in cell number. Moreover, the antiandrogen 
bydroxyflutamide shows agonistic properties by increas- 
ing the cell number of PC-3 cells pre-exposed to [3-IFN. 
When the antiandrogen is tested in combination with 
interferon, it produces a reduction in the 13-IFN-induced 
inhibition of cell growth. It is not known whether these 
unexpected effects are due to the increase in androgen 
receptors or to other mechanisms. 
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It is well known that interferons (IFNs), regarded primar- 
ily as antiviral agents, affect cell growth and differen- 
tiation [17]. Recently published studies have suggested 
that IFNs also influence the expression of steroid hormone 
receptors both in vitro and in vivo [15, 21,25] and sensitize 
breast cancer cells to the antitumor action of anti- 
estrogens [6, 11, 25], drugs that mainly act through the 
estrogen receptor. 
In a previous paper we provided evidence that natural 
beta-interferon (13-IFN) inhibits cell growth of PC-3 cells, 
a human prostatic adenocarcinoma cell line [19]. In 
addition, at concentrations ranging from 100 to 1000 IU/  
ml of culture medium, it produces an enhancement of 
androgen receptor (AR) level, evaluated by a whole cell 
assay [20]. However, data on androgen binding to PC-3 
cells are controversial, some authors reporting that they 
express AR [26] or a very low level of normal AR [4] while 
others have found that they contain only nuclear AR or 
lack AR [3, 10]. 
In the present study we approached this problem again 
by an investigation of the presence and characteristics of
AR in this cell line. Moreover, we explored the interaction 
of 13-IFN with AR, growth fraction and the capability of 
modulating the hormone sensitivity of these cells, which 
have been reported to be androgen-insensitive [10, 18]. 
Materials and methods 
Materials 
13-1FN, induced in human fibroblasts by poly(I) 9 poly(C), was kindly 
supplied by Serono (Rome, Italy). It was dissolved at the appropriate 
concentrations in culture medium. 5c~-Dihydro[l,2,4,5,6,7- 
3H]testosterone ([3H]DHT) (specific activity 100Ci/mmol) was 
purchased from Amersham (UK). 5a-Dihydrotestosterone (DHT) 
was provided by Sigma (St. Louis, Mo.). The antiandrogen hydroxy- 
flutamide (FOH) was a gift from Dr. R. Neri (Schering Corporation, 
Brookfield, N.J.). These compounds were dissolved in ethanol. 
Mouse monoclonal anti-human AR antibody (F39.4.1) against the 
N-terminal domain was produced and characterized as described 
previously [16]. 
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Cells 
PC-3 cell line was a gift from Prof. F. Labrie (Laval University, 
Quebec, Canada). Cells were routinely cultured at 37~ under a 
humidified atmosphere in a 5% CO2 incubator. They were main- 
tained in Dulbecco's modified Eagle's medium (DMEM, Flow 
Laboratories, Irvine, UK), supplemented with 5 % fetal calf serum 
(FCS, Flow Laboratories), 10 mM HEPES buffer (Sigma), 100 IU/ 
ml penicillin, 100gg/ml streptomycin, 2.5 lag/ml amphotericin B
(Flow Laboratories). 
Cell growth experiments 
In the experiments performed to assess the responsiveness to 
androgens and antiandrogens, PC-3 cells were plated at an initial 
density of 20000 cells/ml in 60-ram plastic Petri dishes, in standard 
culture conditions and allowed to attach. Twenty-four hours later 
the medium was renewed with DMEM containing 5% charcoal- 
treated FCS (FCS-CH), HEPES buffer, antibiotics and DHT or 
FOH concentrations ranging from 10 -9 to 10 -6 M. Culture medium 
was again changed after 3 days. Control plates, which received 
vehicle only, were run in parallel. 
In experiments performed to assess whether pretreatment of PC-3 
cells with ~-IFN would modify the effect of subsequent androgen or 
antiandrogen administration, cells were plated in standard culture 
conditions at a density of 25000 cells/ml in 100-mm plastic Petri 
dishes and allowed to attach. Twenty-four hours later the medium 
was changed with DMEM containing ~3-IFN at the concentration of
1000 IU/ml. After 3 days of treatment, cells were trypsinized and 
plated in 60-mm plastic Petri dishes at a density of 20000 cells/ml in 
standard culture conditions. Twenty-four hours later the medium 
was renewed with DMEM containing 5% FCS-CH, HEPES buffer, 
antibiotics and either DHT or FOH concentrations ranging from 
10-9 to 10 _6 M. In control plates medium containing vehicle only was 
present. 
In experiments in which [3-IFN and FOH were combined, cells 
were plated at a density of 20000 cells/ml in 60-mm plastic Petri 
dishes and 24 hours later medium was renewed with DMEM 
containing 5% FCS-CH, HEPES buffer, antibiotics and concentra- 
tions of FOH ranging from 10 9 to 10-6M associated with 100 or 
1000 IU/ml of 13-IFN. 
In all the experiments the final ethanol concentration i the 
control and treated cell medium never exceeded 1%. Cell counts 
were performed with a hemocytometer after 6 days of treatment 
with the drugs. Cell viability was assessed by trypan blue dye 
excIusion. 
Androgen receptor binding studies (whole cell assay) 
PC-3 cells were plated out at an initial density of 20000 cells/ml in 60- 
mm plastic Petri dishes in standard culture conditions. Twenty-four 
hours later DMEM was changed and cells were incubated with 
DMEM supplemented with 1000 IU/ml J3-IFN. This concentration 
of 13-IFN was chosen because, in our previous experience, it 
produced the greatest enhancement of AR, evaluated using a single 
saturating dose (10 nM) of [3H]DHT [20]. In control plates no ]3-IFN 
was added. After 3 days the medium was renewed with DMEM 
supplemented with 5% FCS-CH, HEPES buffer and antibiotics. 
Twenty-four hours later, monolayers were washed three times with 
DMEM and left in this medium for 1 h in the incubator. Then, 
medium was removed and cells incubated in triplicate with DMEM 
containing increasing concentrations of [3H]DHT (0.1-10nM), 
either in the presence or in the absence of a 100-fold excess of 
unlabeled DHT, for 1 h at 37~ At the end of incubation, cells were 
washed three times with Hanks' balanced salt solution to remove 
free steroids and monolayers were incubated with 80% ethanol at 
room temperature overnight o extract radioactivity. Ethanol ex- 
tracts were transferred to vials and radioactivity counted in a liquid 
scintillation counter. Parallel cultures were processed in the same 
manner but did not receive ither labeled or unlabeled hormone and 
were used to determine cell number. This allowed AR to be expressed 
as sites per cell. 
Immunocytochemicat analysis 
Immunocytochemical analysis was carried out on coverslips with 
PC-3 cells plated at a density of 20000 cells/ml in standard culture 
conditions and treated with [3-IFN at concentration of 1000 IU/ml. 
At the end of 13-IFN treatment, medium was removed, coverslips 
were washed with phosphate-buffered saline (PBS) and fixed with 
4% buffered formaldehyde for 5 min. Slides were then rinsed with 
PBS and post-fixed in methanol 100% for 5 rain at 20~ 
followed by acetone 100% for the same time and at the same 
temperature. Slides were preincubated for 10 min with 0.1% 
buffered bovine serum albumin (BSA) to block nonspecific bind- 
ing and then covered with a 1:1000 dilution of monoclonal 
antibody F39.4.1 [16] at 4~ overnight. After washing, reactivity 
was visualized using an immunoperoxidase procedure. Peroxidase- 
conjugated rabbit antimouse IgG (Dako Laboratories, Denmark), 
diluted 1:50 in PBS, was added as the conjugate for 1 h at room 
temperature followed by 3,3'-diaminobenzidine tetrahydrochloride 
and hydrogen peroxide mixture as the substrate for 10 rain. As a 
negative control coverslips with lymphatic tissue sections were 
used (not shown). 
Cell cycle analysis 
PC-3 cells were trypsinized and plated in 100-mm plastic Petri dishes 
at 20 000 cells/ml in standard culture conditions. Twenty-four hours 
later, medium was renewed with fresh medium with or without 
1000 IU/ml ]3-IFN. At 24, 48, 72 and 96 h of treatment, PC-3 cells 
were trypsinized and fixed in cold PBS-buffered acetone-methanol 
mixture for 30 min. Then the cells were centrifuged, resuspended in
cold PBS, and stored at 4~ For the analysis cells were again 
centrifuged and resuspended with 500 pl DNA staining solution. 
This was freshly prepared and contained 50 gg/ml propidium iodide 
(PI), 1-2 mg/ml (50-75 Ku/mg) RNase A and 0.1% Nonidet P40 in 
PBS. Cells were incubated for 30 rain at room temperature followed 
by cooling on ice, and analyzed both immediately and after an 
overnight incubation at 4~ Flow cytometric analysis was ac- 
complished with a Becton-Dickinson FACScan equipped with a 15- 
mW 488-nm argon laser and suitable filter set for the red emission of 
PI. Fluorescence signal was collected with linear amplification, the 
flow rate was maintained at less than 300 cells per second and the 
data were collected, stored and analyzed in a Consort 30 Data 
Management System (Hewlett-Packard series 300 computer). For 
each experimental condition 30000 events were acquired. The 
percentage of cells in the various phases of the cell cycle, i.e., G0-G~, 
S and G2-M, was determined by computerized cell cycle analysis of 
the DNA histograms performed with a commercially available 
software package (Sum of Broadened Rectangles, Becton-Dickin- 
son), 
Statistical analysis 
Data from all cell proliferation experiments were subjected to 
analysis of variance; multiple comparisons were made using Fisher's 
test only if the analysis of variance demonstrated a significant effect 
of the treatment. 
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Table I Effect of DHT or FOH on the growth of PC-3 cells with or 
without pre-exposure to 1000 IU/ml [3-IFN 
Compound Concen- Cell no. without Cell no. with 
tration pre-exposure pre-exposure 
(M) to I3-IFN to 13-IFN 
(mean % of (mean % of 
control • SE) control _+ SE) 
DHT 10 9 103.9 _+ 11.4 134.5 + 11.1 b 
10 -8 109.8 • 11.4 123.0 + 11.1 b 
10 -7 110.1 + 11.0 120.9 _+ 11.8 b 
10 6 100.0 + 13.0 112.7 + 6.2 a 
FOH 10 9 93.1 • 7.8 127. l + 3.5 b 
10 -8 97.1 + 8.3 123.9 _+ 3.2 b 
l0 7 102.7 • 6.1 125.6 • 7.8 b 
10 6 109.8_+ 7.2 118.6 • 5.9 b 
DHT, Dihydrotestosterone; FOH, hydroxyflutamide 
Cell number was determined after 6 days of treatment with DHT or 
FOH. Values represent the mean of nine observations from three 
separate experiments 
a P < 0.05 (Fisher's test vs control: see Materials and methods) 
b p < 0.01 (Fisher's test vs control: see Materials and methods) 
Table 2 Effect of FOH combined with I3-IFN on the growth of PC-3 
cells 
Compounds Concentration Cell number 
(mean % of 
control + SE) 
~3-IFN 100 IU/ml 73.6 + 7.2" 
FOH 10-9M + [3-IFN, 100 IU/ml 77.2 • 12.8 a 
10 -8 M + 13-IFN, 100 IU/ml 78.4 + 6.4 a 
10 -7 M + 13-IFN, 100 IU/ml 74.3 • 7.4 a 
10 6M + 13-IFN, 100 IU/ml 91.0 • 8.7 b 
13-IFN 1000 IU/ml 44.0 _+ 9.8 a 
FOH 10-9M * [3-IFN, 1000 IU/ml 54.1 + 10.9 a 
10 8 M + ~-IFN, 1000 IU/ml 55.6 + 14.2 a 
10 7M + [3-IFN, 1000 IU/ml 57.0 • 9.7 a 
10-6M + ]3-IFN, 1000 IU/ml 62.2 • 10.6 "'b 
FOH, Hydroxyfiutamide; fl-IFN, beta-interferon 
Cell number was determined after 6 days of treatment. Values 
represent he mean of nine observations from three separate 
experiments 
a p < 0.01 (Fisher's test vs control: see Materials and methods) 
bP<0.05 (Fisher's test vs 13-IFN treated cells: see Materials and 
Methods) 
Results 
Growth studies 
The addit ion of  DHT and FOH to PC-3 cells did not 
produce any statist ical ly significant growth variat ion after 
6 days of exposure to the drugs (Table 1). Conversely, 
sensitivity of PC-3 cells to both DHT and FOH appeared 
to be modif ied by 13-IFN pretreatment.  Pre-exposing PC-3 
cells to 1000 IU /ml  I3-IFN induced a statist ical ly signifi- 
cant increase in cell number  at all DHT and FOH con- 
centrations evaluated after 6 days of  treatment (Table 1). 
No statistical ly signif icant difference in the effect pro- 
duced by the different concentrat ions of DHT or FOH 
was seen. 
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Fig.1 Saturation analysis of dihydrotestosterone (DHT) binding to 
PC-3 cells in monolayers. Results from a representative experiment 
are expressed as specific [3H]DHT binding for control and beta- 
interferon (~3-IFN)-treated cells; 9 control; 9 I3-IFN, 1000 IU/ml 
I FN  alone reduced cell growth by approx imate ly  30% 
at 100 IU /ml  and 60% at 1000 IU/ml .  The combinat ion of 
1000 IU /ml  [3-IFN with different concentrat ions of  FOH 
revealed that 10 6M FOH part ia l ly counteracted the 
ant• effect of 13-IFN while the associat ion of 
I FN  with the other concentrat ions of FOH did not result 
in any var iat ion of the ant• effect observed 
with IFN  alone. This was seen also when 10 .6 M FOH was 
combined with 100 IU /ml  ]3-IFN (Table 2). 
In all experiments performed,  viabi l ity testing showed 
that >95% of adherent cells remained viable. A few 
nonviable f loating cells were noted in the supernatants.  
Androgen receptor studies 
Figure 1 i l lustrates the specific binding of [3H]DHT in 
untreated and 13-IFN-treated PC-3 cells. The saturat ion 
curves show a biphasic trend for both treated and 
untreated cells with an apparent  plateau observed between 
2 and 3 nM for the first binding component.  These data 
yielded a nonl inear Scatchard plot (not shown) which did 
not al low accurate est imation of either the associat ion 
constant or the number of  binding sites. Hil l  analysis [8] of 
the data yielded a Hil l  coefficient of  1.2 for control  cells 
and 1.3 for treated cells, suggesting the presence of 
mult iple binding components with posit ive cooperativity.  
A reasonable stimate for Bma x of type I binding compo-  
nent can be obtained from the saturat ion curves, specific 
binding being higher in PC-3 cells exposed to [3-IFN. KD 
was estimated from the Hil l  p lot analysis. The binding 
characteristics of type I AR  are summarized in Table 3. 
At  the concentrat ions used the saturat ion of a second 
class of binding sites was apparent ly  between 8and 10 nM. 
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Fig. 2 Immunocytochemical staining of PC-3 cultured for 3 days in 
the absence of ~-IFN. Original magnification • 100 
Fig. 3 Immunocytochemical staining of PC-3 cells exposed for 
3 days to 1000 IU/ml ]3-IFN. Original magnification • 100 
Table 3 Type I androgen binding sites in PC-3cells 
Parameters Treatment 
Control ]3-IFN, 1000 IU/ml 
Sites per cell 2124.8 _+ 516.7 6523.1 + 880.0 
Saturation (nM) 2.12 2.12 
KI) (nM) 0.57 _+ 0.027 0.61 _+ 0.195 
Data refer to the mean _+ SE of three different experiments 
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Fig. 4 Computerized mathematical an ysis (Sum of Broadened 
Rectangles model) of the histograms of PI-3 cells DNA distribution 
obtained by flow cytometry. Values are from three different experi- 
ments. Open symbols, control cells; filled symbols, cells treated with 
1000 IU/ml [3-IFN. Cells with the same DNA content (i.e. Go and GI, 
or G2 and M) cannot be discriminated by the single-parameter assay 
used here, and are therefore counted as single populations 
Immunocytochemical studies 
The presence of AR in PC-3 cells was confirmed by results 
obtained using the newly developed highly specific anti- 
AR monoclonal antibody F39.4.1. Figure 2 shows the 
staining pattern of untreated PC-3 cells, which exhibited a
specific nuclear staining with a wide range of intensity. [3- 
IFN at 1000 IU/ml seemed to induce a higher number of 
nuclei to become positive with an enhanced staining 
intensity (Fig. 3). Viability testing performed after the end 
of [3-IFN treatment showed that > 90% of adherent cells 
were viable. 
Cell cycle studies 
Exposure of PC-3 cells to 1000 IU/ml [3-IFN for up to 96 h 
altered the cell cycle distribution slightly. As depicted in 
Fig. 4, there was a detectable increase of cells in the G0-G1 
phase of the cycle, with a concomitant, although less 
marked, reduction of cells in the S and G2-M phases. 
These effects first became vident after 72 h of treatment. 
Discussion 
The present study confirms our previous report on the 
presence of AR in the cell line PC-3 [20]. In our experi- 
ments AR were evaluated using whole cell binding to 
avoid the bias of fractionation and homogenization 
procedures. Moreover DHT was used as ligand in cultures 
that had been maintained in medium supplemented with 
unstripped FCS. Other published studies regarding AR in 
PC-3 cells have been conflicting. Some authors found no 
detectable androgen binding in PC-3 cells [10], while 
others found only nuclear receptors, drawing the con- 
clusion that these cells have an altered receptor system [3]. 
More recently, Culig et al. [4], using the polymerase chain 
reaction, concluded that  low level of normal AR is 
present in PC-3 cells. On the other hand, it has been 
suggested that in human prostatic ancer the presence of 
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nuclear receptors correlates better with androgen sensi- 
tivity than does the presence of cytosolic receptor [5, 7]. 
The high level of heterogeneity and genetic instability of 
PC-3 ceils [2, 10], which in different laboratories may 
present different characteristics, could explain the contro- 
versial data. Moreover, it is important o note that the 
demonstration f steroid hormone receptors in monolayer 
cell cultures is critically dependent on the cell density, the 
conditions provided prior to analysis and the ligand used 
in the assay. AR level in PC-3 ceils is, however, lower than 
that of cells known to be androgen-responsive, such as 
LNCaP. AR in LNCaP are found to be expressed at a high 
level using different tracers (i.e., DHT or R1881) and 
different culture conditions [23, 27]. 
Two classes of androgen binding sites have been 
identified in PC-3 cells. The KD of type I AR we found in 
PC-3 cells is similar to that reported in literature for other 
cell lines [27]. The presence of a double class of AR has 
been reported by other authors in both normal and 
neoplastic prostatic ells [ 13, 24]. The role of type I IAR is 
still debated. They could represent a storage compartment 
for maintaining elevated levels of intracellular androgens 
or be involved in the response to other ligands as 
hypothesized for the type II estrogen receptor [12]. 
Treatment of PC-3 cells with [3-IFN produces an increase 
in type I AR that leaves the KD unchanged. Moreover, it 
also seems to influence the type II binding component. 
The presence of AR in PC-3 cells was confirmed using 
an anti-AR monoclonal antibody and the receptors ap- 
peared to be preferentially ocated in the cell nucleus. A 
high degree of heterogeneity was observed, with strongly 
positive, weakly positive and non-stained nuclei. Such 
heterogeneity s consistent with the reported heterogeneity 
of the PC-3 cell line [2, 10]. 13-IFN treatment seems to 
produce an increase in strongly positive cells with respect 
to total cells. 
As some steroid hormone receptors are preferentially 
synthesized during specific phases of the cell cycle [9, 22], 
it was important o ascertain whether 13-IFN selectively 
blocked the normal progression of PC-3 cells through the 
different phases of the cell cycle. We observed that 13-IFN 
did not exert a selective activity on the cell cycle, although 
it induced a detectable r duction in the percentage of cells 
in the proliferative compartments, i.e. S and G2-M. Such a 
decrease in the growth fraction is consistent with the 
reduced number of cells recovered from [3-IFN-treated 
cultures [19]. Thus, it is concluded that the enhanced AR 
content observed upon 13-IFN treatment does not merely 
reflect a concomitant alteration of cell cycle distribution, 
but rather a specific activity of [3-IFN on the physiological 
regulation of AR. 
In keeping with a previous report [1, 18], PC-3 cells 
were unresponsive both to androgen as reported by other 
authors [10] and antiandrogen. This androgen and antian- 
drogen insensitivity could be due to the relatively low AR 
level. Moreover, PC-3 cells are composed of several 
subpopulations of which only a minority seems to express 
AR strongly, as demonstrated by the immunocytochemi- 
cal assay. Pretreating cells with ]3-]FN allowed the re- 
sponse to androgen and antiandrogen i  terms of an 
increase in cellular growth. 13-IFN-induced modulation of 
AR could be involved in this phenomenon. The prolifera- 
tive effect of FOH has been already described by other 
authors in LNCaP cells, in which an altered AR is present 
[14, 26, 27]. This apparently paradoxical phenomenon can 
be explained by the binding of the antihormone in the 
absence of the specific hormone. Under such circum- 
stances, the action of the latter cannot be antagonized but 
a slight agonistic effect is likely to occur, following the 
same chain of reactions which characterize activation of a 
hormone-receptor system. 
The interference observed between [3-IFN and FOH in 
association experiments i  well explained by the opposite 
action on cell growth exerted by the two drugs. The 
stimulation of cell growth produced by FOH counteracts, 
at least in part, the antiproliferative effect of [3-IFN. This 
effect seems to be dose-dependent, because the lower dose 
of J3-IFN (100 IU/ml) was less effective in antagonizing 
FOH stimulation than the higher. Although it is possible 
to hypothesize that an augmentation of AR is involved in 
the phenomenon, we are not able, at present, to quantify 
the relevance of the receptor increase to the sensitivity of 
PC-3 cells to androgens and antiandrogens. 
The results of the present study confirm that 13-IFN 
enhances AR in PC-3 cells and indicate that the two classes 
of binding sites are modified by 13-IFN treatment. This is 
of great interest, because not only the intracellular accum- 
ulation of the hormone, which is likely to be dependent on 
type I IAR, but also the interaction of the hormone with its 
effective mediator, which is supposed to be a type I 
receptor, is affected. In addition, our data suggest that 13- 
IFN may restore hormone sensitivity in androgen or 
antiandrogen insensitive cells, but further studies are 
needed, in view of possible clinical applications. 
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